DIabetes summit Prof. Mathieu concludes that clinical practice lags behind regarding available evidence on management of T2DM. She considers what causes this gap and who needs to act to change it.
Diabetes summit Prof. Cosentino considers the how and why of development of clinical guidelines, in light of new recommendations in the 2019 ESC/EASD diabetes guidelines.
Diabetes summit Prof. Lehmann considers factors that may play a role when diabetes guidelines are not adequately implemented, and how these barriers may be overcome.
This e-learning course focusses on the effect of GLP-1RAs on kidney outcomes in diabetes patients. Member registration (free) is needed to enroll in this course.
The CVD-REAL 3 study assessed the rate of eGFR decline and other kidney outcomes in T2DM patients who started SGLT2i treatment compared with other glucose-lowering agents
Icosapent ethyl has now been approved by the FDA to reduce CV risk in adult patients with elevated triglyceride levels (≥150 mg/dL) and established CVD or T2DM and ≥two additional CV risk factors.
Prof. Ray gives a presentation on the rationale, design and CV outcomes of the BETonMACE trial, in which the BET inhibitor apabetalone was evaluated compared to placebo in high-risk patients.
AHA 2019 The BETonMACE trial evaluating apabetalone did not reduce the primary composite efficacy outcome, nor key secondary outcomes, in T2DM patients with recent ACS and low HDL-c.
AHA 2019 This analysis of DAPA-HF shows that dapagliflozin consistently reduced worsening HF events and CV death and improved symptoms in patients with HFrEF, irrespective of diabetes status.
A post hoc analysis of ADVANCE and ADVANCE-ON data shows that a eGFR slope of -3 mL/min/1.73m² was associated with increased risk of clinical outcomes in patients with T2DM.
A systematic review and meta-analysis of four trials shows that SGLT2 inhibition reduces the risk for dialysis, kidney transplantation, or death due to kidney disease in T2DM patients.
Based on the CREDENCE renal outcomes trial, the FDA granted the approval of canagliflozin to treat diabetic kidney disease (DKD) and reduction of HF hospitalization in patients with T2DM and DKD.